Author Archive Marian Vasilescu
GreenSpace Brands Announces Acquisition of US Based Galaxy Nutritional Foods, Owners of the Go Veggie Brand
GreenSpace Brands Inc. (“GreenSpace”) (TSXV: JTR) is pleased to announce today that it has signed a share purchase agreement dated December 20, 2017 to acquire (the “Acquisition”) all of the outstanding shares of Galaxy Nutritional Foods Inc. (“Go Veggie”), which owns the Go Veggie? brand. Go Veggie is one of the leading cheese alternative brands in the United States with distribution in over 12,000 locations through most major US grocery retailers and natural food chains, along with a growing food service business. The plant based dairy alternative market is one of the fastest growing subsets of the natural food market, but has very few established players. Go Veggie has established itself as one of the preeminent brands in the space with some of the best tasting and award winning products.
Greenspace will be holding a conference call to discuss the details of the transaction on December 21st, 2017 at 9:00 EST. The call will be hosted by Matthew von Teichman, President and Chief Executive Officer. Following management’s presentation, there will be a question and answer session for analysts and investors. To participate in the teleconference, dial (647) 427-7450 or 1 (888) 231-8191 (Toll-free). Callers are advised to call five minutes in advance of the call.
A taped rebroadcast will be available beginning at 11:20 am (EST) December 21st, 2017 until 11:59 pm (EST) on December 28th, 2017. To access the rebroadcast, please dial (416) 849-0833 or 1 (855) 859- 2056 and use the passcode 1289656 followed by the number sign.
Overview of the Acquisition
GreenSpace has agreed to purchase Go Veggie for a total consideration of $17.8 million USD, comprised of $4.5 million USD in cash, $7.62 million USD (approximately $9.81million CAD) in GreenSpace common shares (the “Share Consideration”), and a two year vendor take back loan of $5.72 million USD, carrying an 8.5% coupon. Greenspace will issue 7.16 million Common shares at $1.37 per share as part of the transaction, a 14.2% premium to the closing market price on December 19th, 2017.
GreenSpace will be purchasing Go Veggie from Mill Road Capital, a Greenwich, Connecticut based private investment firm focused on investing in and partnering with publicly traded micro-cap companies. Mill Road will become the largest shareholder of GreenSpace as a result of this transaction. Mill Road Capital has a long history of successfully investing in emerging consumer brands throughout Canada and the United States, and this expertise will help support the GreenSpace team as they navigate the US natural food market and US capital markets.
The Share Consideration will be subject to lock-up and escrow pursuant to which approximately 45% of the Share Consideration shall be locked up for 12 months from the closing date, 5% of the Share Consideration shall be in escrow for 13 months from the closing date and the remaining 50% shall be locked-up for 18 months from the closing date, subject to certain exemptions.
Select highlights of the Acquisition include the following:
Go Veggie adds a profitable pre-existing US platform that will enable GreenSpace to launch its most innovative and unique brands into the US;
The acquisition is expected to add significant gross margin dollars to GreenSpace and improve the overall gross margin profile, as well as add incremental adjusted EBITDA in the short term, with more significant growth in adjusted EBITDA over the long term. Go Veggie recorded revenues of $16.3 million USD for their fiscal year ended March, 31, 2017, with strong gross profit margins of approximately 40%.1
Go Veggie has one of the leading brands in what GreenSpace believes to be one of the fastest growing segments of the natural food industry, plant based dairy alternatives. Galaxy has broad based distribution across the United States and an existing high functioning team; and
GreenSpace believes that by supporting updates and amplifying the brand image of Go Veggie, it will be able to further develop its leadership position in the plant based dairy alternatives vertical in North America;
“We couldn’t be more excited to add Go Veggie to the GSB family of brands. With the acquisition of Go Veggie, we enter our most sought after vertical, plant based dairy alternatives. The addition of Go Veggie adds a profitable pre-existing US platform that will enable us to launch our most innovative and unique brands into the US under the expert leadership of one of the most respected people in the US natural food industry, Rick Antonelli, CEO of Go Veggie” comments Matthew von Teichman, CEO of Greenspace, “This is truly a transformative acquisition for us. We will continue to develop their Canadian sales strategy through the leveraging of our current platform and strategically initiate our US development by leveraging their platform. It’s a win-win and the ideal way for us to get going in the US market”
Rick Antonelli, CEO of Galaxy comments, “We’ve been watching GreenSpace for years and have admired the stable of brands they’ve been able to put together in such a short time. We feel that Go Veggie is a perfect addition to that roster of strong brands and with the potential synergies of our team selling their products, and their team selling our products, there’s a significant long term upside for both. I can’t wait to start presenting GreenSpace’s unique and innovative products to the US market and Go Veggie’s existing retail partners.”
The Acquisition is scheduled to close in January 2018, subject to satisfaction of customary closing conditions and approval of the TSX Venture Exchange. Financo, Inc. has acted as the exclusive advisor to Galaxy and Mill Road.
About GreenSpace
GreenSpace is a Canadian-based brand ideation team that develops, markets and sells premium natural food products to consumers across Canada. Greenspace owns and operates the following brands: Love Child Organics., one of the fastest growing brands in Canada and a producer of 100% organic food for infants and toddlers made with the pure, natural and most nutritionally-rich ingredients; Central Roast, a clean snacking brand that has been one of the leading natural food brands in Canada; Rolling Meadow Dairy, Canada’s leading grass fed dairy product line, delivering premium fluid and cultured products across Canada; Life Choices which features premium convenience meat products made with grass fed and pasture raised meats without the use of added hormones and antibiotics; Kiju, the Canadian market leader in the shelf stable organic juice segment; Cedar , the Canadian leader in cold pressed and gut health fresh juices. All brands are wholly owned and retail in a variety of natural and mass retail grocery locations across Canada.
GreenSpace’s filings are also available at www.SEDAR.com
About GO VEGGIE?
Over 40 years ago Galaxy Nutritional Foods Inc. created the cheese alternative category for health-conscious consumers and is proud to remain America’s leading provider of great tasting cheese-free products. Today, under Galaxy’s new brand GO VEGGIE, the company continues to innovate and offer consumers more healthy cheese-free choices. Across its product portfolio – Vegan, Lactose Free, and Lactose & Soy Free – GO VEGGIE offers 55 products across the United States in a wide variety of formats.
For product information, recipes, and more, visit www.goveggiefoods.com. Follow GO VEGGIE on Facebook, Twitter, Instagram, and Pinterest.
About Mill Road Capital
Mill Road Capital is a private investment firm focused on investing in and partnering with publicly traded micro-cap companies in the U.S. and Canada. The firm has flexible, long-term capital with the ability to purchase shares in the open market, buy large block positions from existing shareholders, provide capital for growth or acquisition opportunities, or execute going-private transactions. The firm has raised approximately $670 million of aggregate equity capital commitments and has offices in Greenwich, CT and the San Francisco Bay Area. Mill Road’s investments in Canada include Ten Peaks Coffee Company, a British Colombia based premium green coffee decaffeinator, PRT Growing Services Ltd., the British Columbia based leader in container grown tree seedlings for replanting forests, and Cossette, the largest full service advertising agency in Canada.
More information can be found at http://www.millroadcapital.com.
Forward Looking Information
Certain statements in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements concerning (i) the Acquisition; (ii) the completion of the Acquisition; (iii) anticipated approvals; (iv) the time to the closings; and (v) results of the completion of the Acquisition. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “should”, “plans” or “continue”, or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including, without limitation, the risks that: (1) the information provided to GreenSpace by Galaxy turns out to be misleading, untrue or incomplete; (2) the Acquisition may not be completed for any reason whatsoever, including that regulators may not approve the Acquisition; (3) the closings may not occur as scheduled or at all; and (4) GreenSpace may not achieve the results currently anticipated. Although GreenSpace believes that the expectations reflected in its forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because GreenSpace can give no assurance that such expectations will prove to be correct. In addition to other factors and assumptions which may be identified in this press release, assumptions have been made regarding and are implicit in, among other things, the timely receipt of required regulatory approvals. Details of the risk factors relating to GreenSpace and its business are discussed under the heading “Risk Factors” in the preliminary short form prospectus filed on the date hereof and “Risks and Uncertainties Related to the Business” in GreenSpace’ annual information form dated July 18, 2017, a copy of which is available on GreenSpace’ SEDAR profile at www.sedar.com. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which have been used. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by GreenSpace and described in the forward looking information. The forward-looking information contained in this press release is made as of the date hereof and GreenSpace undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. The forward looking information contained in this press release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release does not constitute or form a part of any offer or solicitation to buy or sell any securities in the United States or any other jurisdiction.
Existing-home sales surged for the third straight month in November
Existing-home sales surged for the third straight month in November and reached their strongest pace in almost 11 years, according to the National Association of Realtors?. All major regions except for the West saw a significant hike in sales activity last month.
Lawrence Yun is chief economist and senior vice president of research at the National Association of Realtors(r). Yun oversees and is responsible for a wide range of research activity for the association including NAR’s Existing Home Sales statistics, Affordability Index, and Home Buyers and Sellers Profile Report. He regularly provides commentary on real estate market trends for its 1 million Realtor(r) members. (PRNewsFoto/National Association of Realtors)
Total existing-home sales1, https://www.nar.realtor/existing-home-sales, which are completed transactions that include single-family homes, townhomes, condominiums and co-ops, jumped 5.6 percent2 to a seasonally adjusted annual rate of 5.81 million in November from an upwardly revised 5.50 million in October. After last month’s increase, sales are 3.8 percent higher than a year ago and are at their strongest pace since December 2006 (6.42 million).
Lawrence Yun, NAR chief economist, says home sales in most of the country expanded at a tremendous clip in November. “Faster economic growth in recent quarters, the booming stock market and continuous job gains are fueling substantial demand for buying a home as 2017 comes to an end,” he said. “As evidenced by a subdued level of first-time buyers and increased share of cash buyers, move-up buyers with considerable down payments and those with cash made up a bulk of the sales activity last month. The odds of closing on a home are much better at the upper end of the market, where inventory conditions continue to be markedly better.”
The median existing-home price3 for all housing types in November was $248,000, up 5.8 percent from November 2016 ($234,400). November’s price increase marks the 69th straight month of year-over-year gains.
Total housing inventory4 at the end of November dropped 7.2 percent to 1.67 million existing homes available for sale, and is now 9.7 percent lower than a year ago (1.85 million) and has fallen year-over-year for 30 consecutive months. Unsold inventory is at a 3.4-month supply at the current sales pace, which is down from 4.0 months a year ago.
“The anticipated rise in mortgage rates next year could further cut into affordability if these staggeringly low supply levels persist,” said Yun. “Price appreciation is too fast in a lot of markets right now. The increase in homebuilder optimism must translate to significantly more new construction in 2018 to help ease these acute inventory shortages.”
First-time buyers were 29 percent of sales in November, which is down from 32 percent both in October and a year ago. NAR’s 2017 Profile of Home Buyers and Sellers – released earlier this year5 – revealed that the annual share of first-time buyers was 34 percent.
Matching the highest share since May, all-cash sales were 22 percent of transactions in November, which is up from 20 percent in October and 21 percent a year ago. Individual investors, who account for many cash sales, purchased 14 percent of homes in November, up from 13 percent last month and unchanged from a year ago.
“The elevated presence of investors paying in cash continues to add a layer of frustration to the supply and affordability headwinds aspiring first-time buyers are experiencing,” said Yun. “The healthy labor market and higher wage gains are expected to further strengthen buyer demand from young adults next year. Their prospects for becoming homeowners will only improve if more lower-priced and smaller-sized homes come onto the market.”
Properties typically stayed on the market for 40 days in November, which is up from 34 days in October but down from 43 days a year ago. Forty-four percent of homes sold in November were on the market for less than a month.
Realtor.com?’s Market Hotness Index, measuring time on the market data and listings views per property, revealed that the hottest metro areas in November were San Jose-Sunnyvale-Santa Clara, Calif.; Vallejo-Fairfield, Calif.; San Francisco-Oakland-Hayward, Calif.; San Diego-Carlsbad, Calif.; and Stockton-Lodi, Calif.
According to Freddie Mac, the average commitment rate for a 30-year, conventional, fixed-rate mortgage increased for the second straight month to 3.92 percent in November from 3.90 percent in October. The average commitment rate for all of 2016 was 3.65 percent.
On the topic of tax reform, NAR President Elizabeth Mendenhall, a sixth-generation Realtor? from Columbia, Missouri and CEO of RE/MAX Boone Realty, says it’s good news homeowners can continue to count on tax incentives such as the mortgage interest deduction and the state and local tax deduction.
“Only 6 percent of homeowners have mortgages exceeding $750,000, and only 5 percent pay more than $10,000 in property taxes, but most homeowners won’t itemize under the new regime,” she said. “While we’re pleased that important homeownership incentives such as the capital gains exclusion survived in conference, additional changes are required to truly incentivize homeownership in the tax code.”
Distressed sales6 – foreclosures and short sales – were 4 percent of sales for the fourth straight month in November, and are down from 6 percent a year ago. Three percent of November sales were foreclosures and 1 percent were short sales.
Single-family and Condo/Co-op Sales
Single-family home sales grew 4.5 percent to a seasonally adjusted annual rate of 5.09 million in November from 4.87 million in October, and are now 3.2 percent above the 4.93 million pace a year ago. The median existing single-family home price was $248,800 in November, up 5.4 percent from November 2016.
Existing condominium and co-op sales increased 14.3 percent to a seasonally adjusted annual rate of 720,000 units in November, and are now 7.5 percent above a year ago. The median existing condo price was $242,500 in November, which is 8.8 percent above a year ago.
Regional Breakdown
November existing-home sales in the Northeast leaped 6.7 percent to an annual rate of 800,000, (unchanged from a year ago). The median price in the Northeast was $273,600, which is 4.0 percent above November 2016.
In the Midwest, existing-home sales jumped 8.4 percent to an annual rate of 1.42 million in November, and are now 6.8 percent above a year ago. The median price in the Midwest was $196,100, up 8.8 percent from a year ago.
Existing-home sales in the South expanded 8.3 percent to an annual rate of 2.34 million in November, and are now 4.0 percent higher than a year ago. The median price in the South was $216,200, up 4.8 percent from a year ago.
Existing-home sales in the West declined 2.3 percent to an annual rate of 1.25 million in November, but are still 2.5 percent above a year ago. The median price in the West was $375,100, up 8.2 percent from November 2016.
The National Association of Realtors?, “The Voice for Real Estate,” is America’s largest trade association, representing 1.3 million members involved in all aspects of the residential and commercial real estate industries.
NOTE: For local information, please contact the local association of Realtors? for data from local multiple listing services. Local MLS data is the most accurate source of sales and price information in specific areas, although there may be differences in reporting methodology.
1 Existing-home sales, which include single-family, townhomes, condominiums and co-ops, are based on transaction closings from Multiple Listing Services. Changes in sales trends outside of MLSs are not captured in the monthly series. NAR rebenchmarks home sales periodically using other sources to assess overall home sales trends, including sales not reported by MLSs.
Existing-home sales, based on closings, differ from the U.S. Census Bureau’s series on new single-family home sales, which are based on contracts or the acceptance of a deposit. Because of these differences, it is not uncommon for each series to move in different directions in the same month. In addition, existing-home sales, which account for more than 90 percent of total home sales, are based on a much larger data sample – about 40 percent of multiple listing service data each month – and typically are not subject to large prior-month revisions.
The annual rate for a particular month represents what the total number of actual sales for a year would be if the relative pace for that month were maintained for 12 consecutive months. Seasonally adjusted annual rates are used in reporting monthly data to factor out seasonal variations in resale activity. For example, home sales volume is normally higher in the summer than in the winter, primarily because of differences in the weather and family buying patterns. However, seasonal factors cannot compensate for abnormal weather patterns.
Single-family data collection began monthly in 1968, while condo data collection began quarterly in 1981; the series were combined in 1999 when monthly collection of condo data began. Prior to this period, single-family homes accounted for more than nine out of 10 purchases. Historic comparisons for total home sales prior to 1999 are based on monthly single-family sales, combined with the corresponding quarterly sales rate for condos.
2 November’s monthly increase of 5.6 percent is the largest monthly gain since December 2015 (12.1 percent), which was influenced by delayed closings resulting from the rollout of the Know Before You Owe initiative in late 2015.
3 The median price is where half sold for more and half sold for less; medians are more typical of market conditions than average prices, which are skewed higher by a relatively small share of upper-end transactions. The only valid comparisons for median prices are with the same period a year earlier due to seasonality in buying patterns. Month-to-month comparisons do not compensate for seasonal changes, especially for the timing of family buying patterns. Changes in the composition of sales can distort median price data. Year-ago median and mean prices sometimes are revised in an automated process if additional data is received.
The national median condo/co-op price often is higher than the median single-family home price because condos are concentrated in higher-cost housing markets. However, in a given area, single-family homes typically sell for more than condos as seen in NAR’s quarterly metro area price reports.
4 Total inventory and month’s supply data are available back through 1999, while single-family inventory and month’s supply are available back to 1982 (prior to 1999, single-family sales accounted for more than 90 percent of transactions and condos were measured only on a quarterly basis).
5 Survey results represent owner-occupants and differ from separately reported monthly findings from NAR’s Realtors?Confidence Index, which include all types of buyers. Investors are under-represented in the annual study because survey questionnaires are mailed to the addresses of the property purchased and generally are not returned by absentee owners. Results include both new and existing homes.
6 Distressed sales (foreclosures and short sales), days on market, first-time buyers, all-cash transactions and investors are from a monthly survey for the NAR’s Realtors? Confidence Index, posted at nar.realtor.
NOTE: NAR’s Pending Home Sales Index for November is scheduled for release on December 27, and Existing-Home Sales for December will be released January 24; release times are 10:00 a.m. ET.
From https://www.prnewswire.com/news-releases/existing-home-sales-soar-56-percent-in-november-to-strongest-pace-in-over-a-decade-300573924.html
Cancer Vaccine at Medisun Regenerative Medical Center and Health Summit
Medisun Regenerative Medical Center and Health Summit
Cancer Vaccine | White House Cancer Lunar Plan | Cancer Proton Beam Treatment
ShenZhen- Hong Kong-GuangZhou
The Medisun Medical Health Summit, co-sponsored by Medisun Regenerative Medical Group, New Life Group and Sunshine Medical Group, was held in Shenzhen, Hong Kong and Guangzhou from September 6 to 9, 2017. The theme of this summit is centered around the prevention and treatment of cancer. The authoritative release of cancer vaccine is the strongest focus of this summit. 
Medisun Medical Group has invited a number of authoritative scientists, medical experts, industry leaders, government agency representatives, business leaders and socialites from the United States, Europe, Japan, Hong Kong and Mainland China to collaborate on cancer prevention worldwide. Leading medical health consultations such as therapeutic technologies, industry regulatory development, and medical platform construction have been fully explored. Nearly 5,000 entrepreneur representatives, medical experts and doctors from the Chinese health industry participated in the listening and sharing. 
Dozens of media interviews and reports at the summit
Madison Cancer Vaccine Launch Ceremony
Chairman Danny Wong said: “The advent of cancer vaccine is the strongest gospel of cancer prevention!”
According to the World Health Organization (WHO), approximately 14 million new cancer cases are diagnosed each year worldwide, and this number is expected to reach 21 million by 2030. As global treatment costs rise, cancer prevention measures are becoming more and more important, which has also made cancer prevention and treatment a high-profile international issue. Medisun’s comprehensive introduction of cancer vaccines is undoubtedly the strongest gospel for cancer prevention. The WT1 gene is a gene representing tumorigenesis in humans, and all human cancers are associated with this genetic mutation. The Nobel Institute of Ecological Medical Sciences has discovered a pathway to inhibit mutations in the WT1 gene, which can be vaccinated to produce memory T cells that inhibit WT1 gene mutations, which are immune to humans.
In addition, Medisun is also committed to the development and clinical use of a variety of other vaccines. Most of the vaccine technology comes from the United States, investing in rapid response to the pandemic virus and cancer control vaccine technology platform, with a market size of more than 2 billion US dollars. The vaccines invested by Medisun can be modularized in Asia and China to produce vaccines that are fully compliant with the United States. Including: Zika virus, Chikungunya fever, Zika/Chikununya heat combination, Ebola virus, human papillomavirus HPV treatment vaccine, head and neck cancer, cervical cancer, cervical lesions, simple Herpesvirus HSV, hepatitis C virus HCV, hepatitis B virus HBV,etc.
Mr. Danny Wong, Chairman of Medici Medical Group, was interviewed by the media about the release of cancer vaccine.
Chairman Danny Wong specifically said: “China’s rapid economic development over the past 20 years has been accompanied by a wave of globalization. China has integrated into the international community in various fields. At the same time, China has introduced high-standard medical technologies and services from Europe, the United States and Japan. It is our mission to make full use of Hong Kong’s advantages as a mature international metropolis and special geographical factors to provide the world’s most advanced medical care to the people of the motherland. 
On-site participants actively asked questions from the cancer vaccine and new cancer treatment technologies to participate in the seminar.
Medisun participates in the White House Cancer Month Plan
Mr. Terry Lierman said: “The greatest progress and breakthrough of mankind is the birth of cancer vaccine!”
Mr. Terry Lierman, a core member of the White House Cancer Month Program, the NIH of the National Institutes of Health, and the founder of the FDA Board of Directors and director of the Meditech Group, said that cancer landing is an amazing cause. It is planned to complete the treatment of 20,000 cancer patients with 60 different technologies worldwide by 2020. This is a task that would have taken at least 10 years to achieve, and we will now achieve it in 5 years. The cancer “moon landing plan” advocated by former US President Barack Obama in 2016 is also the focus of this summit. The plan is led by former Vice President Joe Biden. The goal is to break the boundaries that hinder the cooperation of researchers and accelerate the research of cancer diagnosis and treatment in the future. 5 years to double the progress of anti-cancer research. The six major US cancer “moon landing programs” include cancer vaccines, high-sensitivity cancer early detection, immunotherapy and combination therapy, single-cell genomic analysis of cancer cells and tumor microenvironment cells, new treatments for childhood cancer, and enhanced data. shared. To this end, the United States and Canada, Hong Kong, Germany, Switzerland, Japan, South Korea and other countries, the first-class research units to establish cooperative relations, large-scale joint cancer research and treatment, toward precision Medisun. The Medisun Medical Group is a member of the Cancer Month Program and will also participate in this historic mission. 
Mr. Terry Lierman talks about McGrady’s participation in the White House Cancer Month Plan
Medisun introduces Mayo proton beam therapy
Dr. Michael Haddock said: “The Mayo proton beam is a great advancement in the precise treatment of cancer!”
As the Asian Medical Service Center of the Mayo Clinic in the United States, Medisun invited Dr. Michael Haddock, Chairman of the Mayo Radiation Oncology Clinical Practice Committee and Vice Chairman of the American Society of Surgery Oncology (ACOSOG) Committee to talk about radiotherapy for cancer. Dr. Haddock talked about the current Proton Bean, the world’s leading cancer radiotherapy technology, Mayo currently has the most authoritative equipment, operations and medical team for global proton beam therapy. Mayo’s proton beam therapy program is the exclusive feature of pen beam scanning. It can accurately target tumors and prevent healthy tissues from being affected, thus achieving ideal cancer treatment, especially for treating children with cancer. For cancers with high mortality and lung cancer, proton beam therapy has obvious advantages compared with traditional radiotherapy.
At the Hong Kong Summit, Dr. Michael Haddock (left), the authoritative doctor of Mayo cancer proton beam therapy, answered questions from guests at the scene. 
Dr. Michael Haddock (left) and Mr. Terry Lierman (right), the authoritative doctors of Mayo cancer proton beam therapy, at the Guangzhou Summit.
Japanese NKT immune cell therapy
Dr. Degang said: “Cancer vaccine and NKT immune cell therapy are the strongest partner in cancer prevention and treatment!”
Haruhiro Tokuoka, CEO of Riken Immunization and Reproductive Medisun, Japan, Dr. Degang Governing, talked about immunotherapy for cancer. Japan has always been a pioneer in cancer immunotherapy and has extensive clinical experience. Japan Riken and Medisun have worked closely together and established the Medisun Precision Medical Joint Venture, which applies NKT immunocytotherapy outside the traditional cancer treatment to clinical treatment of various types of cancer in the early, middle and late stages, and has clinically proven to greatly improve cancer patients. High quality of immunotherapy at the same time as quality of life with almost no side effects.
Dr. Kazuoka Kazuo of Japan at the Hong Kong Summit to explain the effectiveness of NKT immune cell therapy in clinical treatment of cancer. 
Dean He Jianxing (second from right) of Guangzhou Medical First Hospital visited the Guangzhou Summit and participated in Dr. Degang Zhiwei (third from left) on cell immunotherapy
Precision Medisun and anti-cancer cancer
Ms. Yanglan said: “As a mother, I chose to give my daughter a HPV cervical cancer vaccine; now the launch of the cancer vaccine is even more exciting!”
In today’s society, everyone is tired of work, and it is often the easiest to ignore their good habits, which leads to the emergence of various diseases . In fact, “health is the first wealth of life”, Emerson’s famous interpretation perfectly interpreted the importance of a healthy life to people. Ms. Yang Lan, a well-known Chinese media person, attended the summit as a guest and shared ideas about health and happiness with the guests. She said that the pain caused by cancer patients to the family cannot be expressed in words, and health is good for every family. Precious, we need to follow the development of science and technology to update our medical knowledge. Nowadays, precision Medisun has brought us new choices. While we are not blindly following, we should fully understand the physical condition of ourselves and our families, and choose the right medical health program for ourselves. 
Ms. Yang Yu shared about cancer treatment. 
Ms. Wu Shuqing, the Honorary Director of the World Trade Center Association and the Standing Committee of the National Committee of the Chinese People’s Political Consultative Conference, was unable to visit the summit due to the temporary overseas meeting. She also sent a congratulatory message to the summit and congratulated Chairman Danny Wong of the Medisun Medical Group: “The summit has deepened Hong Kong with the Chinese mainland again, we are highly concerned about the medical and health industry. Therefore, I believe that Medisun Medical Group will continue its leading position in the field of medical and health care. Since the beginning, I have seen the entire team of Medisun under the leadership of Chairman Danny Wong. Unremitting efforts and dedication, I am convinced that today’s event is only the beginning, I hope that more results will be shared with the whole society.”
As a pioneer in the field of stem cells, cancer prevention and treatment in the world of regenerative , Medisun Medical Group has been committed to introducing the world’s leading cancer prevention and treatment technologies and providing the most advanced, professional and excellent medical and health services to the society. The release of the cancer vaccine is a revolutionary advancement in the field of cancer prevention. Ancient smallpox is terminally ill, and now a single shot of smallpox disappears; in the past, hepatitis B was terminally ill, and now a vaccine is immunized for life; yesterday, cancer is terminally ill, and today’s cancer vaccine keeps cancer away. Time is advancing and science is progressing. We must have a mentality of accepting progress. We believe that cancer prevention can provide shelter for the family and the health and well-being of society. 
Stay tuned: Hong Kong’s latest publication “CAPITAL” magazine in September, cover story “Mr. Danny Wong, Chairman of Medisun Medical Group” and cover story “New Revolution in Medical Industry”.
You can contact the Hong Kong Medisun Regenerative Medical Center to receive a magazine. Contact as below:
Phone: +(852) 2582 0188
Email: info@medisun.hk
WeChat: medisuninfo
Website: www.medisun.hk
****************************************
Medisun Medical Group
Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative products, as well as top hospitals and treatment centers. Located on the 25th floor of Ao Teng Plaza, Kowloon Bay, Hong Kong, the Medisun Reproductive Centre has a 50,000-square-foot stem cell GMP production facility, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to be rigorous and professional. The development process provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. More than 3,000 biomedical tests provide the most predictable health protection for the health of our clients. Medisun has been fully supporting the development of the new life and health platform, and is committed to the deepening of the new products and technologies of regenerative Medisun through this platform, truly benefiting the health of the whole society.
For more details, please visit http://www.medisun.hk/
Hong Kong National Investment and Harvard University Stem Cell Institute starting a strong partnership
Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation.
Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group.
2015-05-11 China Securities Journal
On May 8, 2015, Hong Kong Medisun Regerative Medical Center and National Investment (01227.HK) announced the appointment of Mr. Brock Reeve as the chief stem cell and regenerative medicine investment officer of the two companies.
Mr. Brock Reeve is currently the Executive Director of the Harvard University Stem Cell Institute and has graduated from Yale University and Harvard Business School. Mr. Reeve is solely responsible for the strategy and operations of the Harvard Stem Cell Institute, whose overall goal is to use stem cell biology as a tool and treatment to study and treat major degenerative diseases.
As the Chief Investor of Stem Cell and Regenerative Medicine of Medisun Medical Center, Mr. Brock Reeve will organize and lead a professional investment team to actively select the latest regenerative medicine technologies in overseas markets such as Europe, the United States, and Japan and evaluate their investment value. They will also focus on and invest in the world’s leading stem cell regenerative medicine technology, and actively participate in clinical trials and product commercialization of stem cell technology invested by Medisun Medical Center in Asia.
Medisun Medical Center is the world’s most authoritative investment organization in stem cell and regenerative medicine
As the world’s most authoritative investment organization for stem cells and regenerative medicine, Medisun Medical Center has invested in stem cell treatment technologies including heart, tumor, liver, kidney, AIDS and other diseases, fully demonstrating its investment vision and courage. After working with the Mayo Medical Group in the United States, the Medisun once again joined forces with the Harvard University Stem Cell Institute.
Mr. Danny Wong is both the Chairman of the Medisun Medical Group and National Investment (01227.HK). He has devoted himself to research and investment in the field of stem cells for the past five years. The Medisun currently has more than 300 scientists , medical consultants and investment experts from all over the world. The technologies invested by the group are distributed in Europe, the United States, Japan, Hong Kong and other places, and clinical trials are carried out simultaneously.
China’s first participation in international multi-center global synchronized clinical trials
Medisun Medical Group is committed to bringing the world’s leading stem cell and regenerative medicine technologies to China. The investment in the C-cure stem cell therapy for ischemic heart failure technology, which was invented by Mayo Medical Group, has been clinically tested in Europe and the United States. It will carry out clinical trials in China’s well-known cardiovascular hospitals such as Beijing Anzhen Hospital, Fuwai Cardiovascular Hospital and Shanghai Oriental Hospital with the support of international multi-center policy, giving Chinese hospitals the opportunity to participate in the world’s most advanced stem cell technology clinic. The Medisun also actively promote the commercialization of technology worldwide in the future. Before C-Cure’s great technology and revolutionary products for heart disease were officially launched, Medisun has launched a series of cell regeneration factor products to treat a number of diseases, and the product has entered the market.
Liang Zhen ying visits Harvard University Stem Cell Research Institute and Mr. Brock Reeve to discuss the promotion of stem cell and the development of regenerative medicine industry
Under the general environment of Hong Kong’s adjustment of the whole industry, one of the important measures is to develop the stem cell and regenerative medicine industries. Looking at the huge investment in the stem cell and regeneration field of the Medisun Medical Group, it is revealed that it will inevitably set off a disruptive business model in the market.
The Hong Kong government attaches great importance to the development of stem cells. Following the cooperation with the Caroline Medical School in Sweden, Liang Zhen ying visited the Harvard University Stem Cell Research Institute on May 5 and exchanged views with its Executive Director Brock Reeve to promote the development of the stem cell industry in Hong Kong. This will undoubtedly inject a strong shot into the cooperation between Harvard University and Hong Kong in the field of regenerative medicine. It will promote the promotion of Harvard stem cells in regenerative medicine research and technology in Hong Kong and Asia.
It can be seen that Medisun Medical Group has appointed Mr. Brock Reeve take the helm of the stem cell and regenerative medicine to investment. National Investment (01227.HK), which holds a 30% stake in Medisun Medical Group, is investing in regenerative medicine and the field of stem cells. Mr. Brock Reeve will lead the Medisun Medical Group to become a professional stem cell investment team with global leadership.
The value of the stem cell and regenerative medicine industry under the capital market in China and Hong Kong is immeasurable.
With the upcoming clinical management of stem cells, the development of China’s stem cell and regenerative medicine industry will be unstoppable. Shanghai-Hong Kong Stock Connect and the upcoming Shenzhen-Hong Kong Stock Connect have apparently injected huge sums of money into Hong Kong stocks. The stocks of companies related to the stem cell industry have risen very well, but they are far from satisfactory and far from the technology held by Medisun Medical Center. National Investment (01227.HK), as a shareholder of Medisun Medical Group, is full of confidence in the development of the Group.
Medisun Investment Holdings’ Cardio Biotech plans to enter the US capital market.
Medisun Investment Holdings’ C-cure Stem Cell Therapy for Ischemic Heart Failure has exceeded the number of patients enrolled by the European Food and Drug Administration (EMA) in the Phase III clinical trial in Europe and has been approved by the US Food and Drug Administration (FDA). Enter the third phase of clinical. Cardio, the investment holding company of Medisun, also successfully obtained a new round of financing of 32 million euros in February this year. Its financing quota was oversubscribed and snapped up by European and American institutional investors. Cardio is planning to be listed on the NASDAQ in the United States from the end of May to the beginning of June this year (listed in Belgium and France in 2013), and the large-scale financing plan of Cardio further indicates that the spring of stem cells has really come.
After many years of favor and investment in the field of stem cells and regenerative medicine, and the huge capital investment plan, the Medisun’ next step will be the focus of the market. The capital market’s confidence in its shareholder, National Investment (01227.HK), is already evident in the expectation of its future development.According to analysts, Medisun has planned to launch an overall listing financing plan in Hong Kong in the near future. We believe that Medisun, as a recognized leader in the global stem cell and regenerative medicine field, will surely launch an incredible wave of development in this field.
The News Picture:
P1:
Mr. Brock Reeve is both the chairman of Medisun medical group and National Investment (01227.HK) and a close friend of Mr. Danny Wong during his stay in the United States.They share the same confidence and enthusiasm for stem cell and regenerative medicine.
P2:
Hong Kong Chief Executive Liang Zhen ying visited the Harvard University Stem Cell Institute and exchanged views with the Executive Director, Mr. Brock Reeve, on the development of the stem cell and regenerative medicine industries.
Source: http://www.medisun.hk/
Brock Reeve is the younger brother of the famous American actor Christopher Reeve. Christopher Reeve (September 25, 1952 – October 10, 2004), a New Yorker, famous movie actor, film director, writer, was play in Superman (Kal-El/Clark Kent). He graduated from Cornell University in 1974 with a Bachelor of Arts degree and then entered the Juilliard School in New York. He is also a good friend with another famous actor Robin Williams. In 1978, he starred in the sci-fi film “Superman” for the first time and became a hit. In 1995, an accident occurred during an equestrian competition. The spine was seriously injured and his body was paralyzed. Since then, he has devoted himself to social welfare undertakings and to promote stem cell research. He often holds tour lectures. On October 9, 2004, he died for the myocardial infarction at the age of 52.
